Dual ISH and IHC
Human lung cancer with human PPIB positive control mRNA probe in red, CAM5.2 acidic cytokeratin immunohistochemical staining in green with DAPI as counterstain.
Dual ISH-IHC - Detection of OLFM4 using RNAscope technology and Lyzozyme using IHC
Dual ISH-IHC. Detection of alpha-smooth muscle actin (SMA) using IHC (green) and Olfr558 using RNAscope technology (red)
Analysis of both RNA and protein provides valuable information for understanding the regulation of expression. Both ISH and IHC technologies share common features that make them unique among the protein and RNA detection technologies.
- Morphological context: detection of RNA and protein while conserving the tissue and cell structure
- Similar workflow from sample fixation, pre-treatment, hybridization, signal amplification and data analysis.
Due to the multiple benefits of running both ISH and IHC, and the high robustness of RNAscope® assay, some customers developed a dual ISH-IHC protocol to perform both analyses on the same sample slide. We conducted an interview with 4 researchers who developed their own dual ISH-IHC protocol to provide you some insides on their protocol.
Download the interview and learn from these experts how to develop a dual ISH-IHC protocol.
Kristie Wetzel, Novartis Institutes for
BioMedical Research, Cambridge, MA, USA.
Dr Bradley Spencer-Dene, The Francis Crick
Institute, London, UK.
Wanda Wang, University of Pittsburgh, PA,
Mike Millar, Queen’s Medical Research
Institute,University of Edinburgh,
Application of combined RNA in situ hybridization and multiplex immunohistochemistry to unravel tumor heterogeneity in prostate cancer.
Presented by Dr Nallasivam Palanisamy and Dr Courtney Anderson